focus -WSS

focus

author：fashion 2025-09-06 06:17:03 - browse：7

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

WSS

The new shift in health care is toward less care

Ebola: Gilead Sciences antiviral shows promise as new treatment

Will General Catalyst be the first of many hospital takeovers?

First U.S. drug developed to treat liver disease MASH is approved

As AI in medicine takes off, can 'human in the loop' prevent harm?

First U.S. drug developed to treat liver disease MASH is approved

entertainment

focus

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

WuXi out of biotech trade group, U.S. and China relations to blame

What does generative AI mean for health care? We asked experts

How many hemophilia patients actually want gene therapy?

At least 13 dead in Texas as scorching temps continue

Medicare solvency divides Republicans at the presidential debate

State Dept. review finds Biden bears some blame for Afghanistan failures

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Heart attack and stroke risk calculators need revising

Diversify hospital leadership teams to protect BIPOC patient health

entertainment

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Will General Catalyst be the first of many hospital takeovers?

How to save health care price transparency rules

Ebola: Gilead Sciences antiviral shows promise as new treatment

Medicare solvency divides Republicans at the presidential debate

How many hemophilia patients actually want gene therapy?

focus

hotspot

leisure time

hotspot